TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11779917

Group type: EXPERIMENTAL
Intervention: Angina class 1
Number of subjects: 3122

Group type: EXPERIMENTAL
Intervention: Angina class 2
Number of subjects: 3122

Group type: EXPERIMENTAL
Intervention: Angina class 3
Number of subjects: 3122

Group type: COMPARATOR
Intervention: No angina
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Angina class 1 vs No angina
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Angina class 2 vs No angina
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Angina class 3 vs No angina
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Conventional risk factors
Number of subjects: 3122
Study: 7715228

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent antegrade cold blood cardioplegia
Number of subjects: 30
Study: 2766869

Group type: EXPERIMENTAL
Intervention: Short-course ceftriaxone therapy (4, 6, and 7 days depending on the pathogen)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard-length ceftriaxone therapy (twice as long as short-course)
Number of subjects: 52
Study: 800972

Group type: EXPERIMENTAL
Intervention: Combination of muzolimine (80 mg) and spironolactone (300 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Combination of furosemide (80 mg) and spironolactone (300 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo and spironolactone (300 mg)
Number of subjects: 22
Study: 31196734

Group type: EXPERIMENTAL
Intervention: 1-FIT
Number of subjects: 9787

Group type: COMPARATOR
Intervention: 2-FIT
Number of subjects: 9787
Study: 27613880

Group type: EXPERIMENTAL
Intervention: Active first generation ECs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo ECs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naturalistic smoking week
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active EC week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo EC week
Number of subjects: 24
Study: 26788786

Group type: EXPERIMENTAL
Intervention: BMI ≥30.0 kg/m² (obese)
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: BMI 25.0-29.9 kg/m² (overweight)
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: WHR 0.80-0.84
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: WHR ≥0.85
Number of subjects: 2276

Group type: EXPERIMENTAL
Intervention: Elevated WHR and higher BMI
Number of subjects: 2276
Study: 23539903

Group type: EXPERIMENTAL
Intervention: Ommaya reservoir treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment methods
Number of subjects: 60
Study: 21337032

Group type: EXPERIMENTAL
Intervention: Tubeless PNL (double-J ureteral stent)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional PNL (nephrostomy tube)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tubeless PNL
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional PNL
Number of subjects: 85
Study: 19800704

Group type: EXPERIMENTAL
Intervention: Novel SIB strategy with prescribed mean doses of 46.8 Gy to PTV(risk), 50.6 Gy to PTV(pre_chemo), and 58.1 Gy to PTV(post_chemo) in 25 fractions.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional two-volume SIB plan (ignoring PTV(post_chemo)).
Number of subjects: 10
Study: 17074942

Group type: EXPERIMENTAL
Intervention: First acute treatment step
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Second acute treatment step
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Third acute treatment step
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Fourth acute treatment step
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Overall cumulative remission rate
Number of subjects: 3794

Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up phase
Number of subjects: 3794
Study: 15556256

Group type: EXPERIMENTAL
Intervention: 2% soluble guar gum (fiber-enriched diet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fiber-free diet (control group)
Number of subjects: 20
Study: 11771024

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg/day for the first week and 100 mg/day for the following 5 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (lactose starch tablets, 1 tablet/day for 6 weeks)
Number of subjects: 37
Study: 9670288

Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 100
Study: 7508219

Group type: COMPARATOR
Intervention: LPS group (NSR plus 200 micrograms/kg of lipopolysaccharide)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LPS/NAME group (NSR, LPS, and continuous infusion of 50 micrograms/kg per minute of N‐nitro‐L‐arginine methyl ester)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NAME group (NSR and NAME)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normal saline resuscitation)
Number of subjects: 24
Study: 3169167

Group type: EXPERIMENTAL
Intervention: Double-step stimuli with ISI of 25 or 50 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-step stimuli with ISI of 75 or 100 ms
Number of subjects: 0
Study: 29660572

Group type: EXPERIMENTAL
Intervention: Incorrigibility in D+ group at baseline
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Delusion severity in D+ group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Jumping-to-conclusions (JTC) in D+ and D- groups
Number of subjects: 79
Study: 28879820

Group type: EXPERIMENTAL
Intervention: Healthy Start intervention
Number of subjects: 285
Study: 27017701

Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 mL in 200 mL of 0.9% sodium chloride for 10 days, then 2 tablets twice a day for 25 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment with oral antidiabetic drugs (metformin monotherapy or combined therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no cytoflavin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23170993

Group type: EXPERIMENTAL
Intervention: Therapy dog visits (average duration 12 minutes)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waiting room control (average duration 17 minutes)
Number of subjects: 155
Study: 21224421

Group type: EXPERIMENTAL
Intervention: Ad libitum feeding
Number of subjects: 9
Study: 19481565

Group type: EXPERIMENTAL
Intervention: Cyclopean motion using a random-dot binocular correlogram with a moving square-wave grating defined by binocular correlations
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-order motion (not explicitly defined in the abstract)
Number of subjects: 0
Study: 16551897

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 20
Study: 12918026

Group type: EXPERIMENTAL
Intervention: Metal-on-metal stable prosthesis (Group A) short-term (subgroup A(1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metal-on-metal stable prosthesis (Group A) medium-term (subgroup A(2))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Presurgical patients (Group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reference values (Group C)
Number of subjects: 15
Study: 11010607

Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 3171
Study: 9064235

Group type: EXPERIMENTAL
Intervention: Triclosan containing dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects instructed not to brush before evaluation
Number of subjects: 0
Study: 7878632

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 20
Study: 2466855

Group type: EXPERIMENTAL
Intervention: Red krypton laser photocoagulation
Number of subjects: 0
Study: 31152334

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 151
Study: 30140093

Group type: EXPERIMENTAL
Intervention: Modified BFM regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: BFM 90 protocol
Number of subjects: 0
Study: 27568006

Group type: EXPERIMENTAL
Intervention: Infant massage therapy administered by the mother until term equivalent age (TEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infant massage therapy
Number of subjects: 60
Study: 25614529

Group type: EXPERIMENTAL
Intervention: Care of a Betta splendens pet fish
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Care of a Betta splendens pet fish (younger adolescents 10-13 years)
Number of subjects: 28
Study: 23942774

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg + gp100 vaccine
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg + placebo
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Ipilimumab (all groups)
Number of subjects: 676

Group type: COMPARATOR
Intervention: gp100 vaccine alone
Number of subjects: 676
Study: 21351636

Group type: EXPERIMENTAL
Intervention: Intervention group (stage theory of organizational change)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 479
Study: 18400731

Group type: EXPERIMENTAL
Intervention: Red grape juice (RGJ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Red grape juice (RGJ) + Vitamin E
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 32
Study: 17345838

Group type: EXPERIMENTAL
Intervention: cetirizine 10mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: desloratadine 5mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: fexofenadine 120mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: fexofenadine 180mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: levocetirizine 5mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: loratadine 10mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 12707129

Group type: EXPERIMENTAL
Intervention: remifentanil 2 micro g/kg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: remifentanil 3 micro g/kg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: remifentanil 4 micro g/kg
Number of subjects: 105
Study: 10972634

Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5 mg)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sumatriptan (100 mg)
Number of subjects: 253
Study: 8958893

Group type: EXPERIMENTAL
Intervention: 400 ppb nitrogen dioxide (NO2) + 200 ppb sulphur dioxide (SO2)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 13
Study: 1347965

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 29
Study: 3513530

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 546

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 546

Group type: COMPARATOR
Intervention: Clonidine withdrawal
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Guanfacine withdrawal
Number of subjects: 546
Study: 28540570

Group type: EXPERIMENTAL
Intervention: 250 mg magnesium oxide supplements daily for 12 weeks
Number of subjects: 70
Study: 27207543

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg once daily for 10 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Exendin [9-39] (high-dose intravenous infusion)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24976347

Group type: EXPERIMENTAL
Intervention: Primary Care Triple P training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control residents
Number of subjects: 0
Study: 23446891

Group type: EXPERIMENTAL
Intervention: Low-palmitic acid and high-oleic acid diet (HOA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-palmitic acid diet (HPA)
Number of subjects: 32
Study: 20497977

Group type: EXPERIMENTAL
Intervention: Fetal growth restriction (FGR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normally grown fetuses (Control)
Number of subjects: 200
Study: 18468014

Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg i.v. (Group M, n = 101)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg i.v. with fentanyl 25 microg (Group MF, n = 100)
Number of subjects: 210
Study: 15915034

Group type: EXPERIMENTAL
Intervention: 75 microg clonidine plus 500 microg neostigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 microg clonidine plus 750 microg neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 microg clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 750 microg neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 75 microg clonidine plus 250 microg neostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ropivacaine
Number of subjects: 0
Study: 12832366

Group type: EXPERIMENTAL
Intervention: EFORT
Number of subjects: 110

Group type: COMPARATOR
Intervention: CCT
Number of subjects: 110
Study: 11056328

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 8897562

Group type: COMPARATOR
Intervention: Prednisone, 40 mg/m2 on alternate days for 12 months (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prednisone, 40 mg/m2 on alternate days for 12 months plus a 90‐day course of daily cyclophosphamide, 2.5 mg/kg in a single morning dose (experimental group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (control and experimental)
Number of subjects: 60
Study: 1510519

Group type: EXPERIMENTAL
Intervention: Automated closed-loop titration system
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Manual nitroprusside titration
Number of subjects: 1089
Study: 6356343

Group type: EXPERIMENTAL
Intervention: Miconazole gel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nystatin suspension
Number of subjects: 51
Study: 31415797

Group type: EXPERIMENTAL
Intervention: 4 Gy x 5
Number of subjects: 203

Group type: COMPARATOR
Intervention: 3 Gy x 10
Number of subjects: 203
Study: 30407098

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (PEMBRO)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Ipilimumab + Nivolumab (IPI+NIVO)
Number of subjects: 400
Study: 26937921

Group type: EXPERIMENTAL
Intervention: Pure oxygen (FiO2=100%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Medical air (FiO2=21%)
Number of subjects: 17
Study: 24798395

Group type: EXPERIMENTAL
Intervention: 6‐h self‐management programme
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 207
Study: 22144721

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 56

Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 56
Study: 20200550

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study: 17659823

Group type: EXPERIMENTAL
Intervention: Tuna fish oil
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 16336487

Group type: EXPERIMENTAL
Intervention: Medium dose of a new uro-selective alpha-blocker
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: High dose of a new uro-selective alpha-blocker
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Low dose of a new uro-selective alpha-blocker
Number of subjects: 536
Study: 12386911

Group type: EXPERIMENTAL
Intervention: SCOFF administered orally
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: SCOFF administered in written format
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: SCOFF administered verbally first
Number of subjects: 185
Study: 10363956

Group type: EXPERIMENTAL
Intervention: Categorical task (judging whether a dot was above or below a horizontal line)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordinate task (judging the distance between the dot and the bar)
Number of subjects: 0
Study: 8576893

Group type: EXPERIMENTAL
Intervention: Combination therapy including a diuretic
Number of subjects: 102

Group type: COMPARATOR
Intervention: Combination therapy without a diuretic
Number of subjects: 102

Group type: COMPARATOR
Intervention: Single drug treatment (hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem-SR, prazosin)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Combinations containing prazosin
Number of subjects: 102
Study: 2196311

Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) 40 KE X 1/W
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) 20 KE X 3/W
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) 5 KE X 3/W
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 377202

Group type: EXPERIMENTAL
Intervention: 25 units of dl‐alpha tocopherol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29866635

Group type: EXPERIMENTAL
Intervention: 5-minute straw phonation exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10-minute straw phonation exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 24
Study: 28594709

Group type: EXPERIMENTAL
Intervention: Antioxidant (AOX) supplementation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 93
Study: 25687539

Group type: EXPERIMENTAL
Intervention: Clobazam (CBZ)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clonazepam (CLN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tolterodine (TLT)
Number of subjects: 25
Study: 23400548

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2.4 gm/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 4.8 gm/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2.4 gm/day and 4.8 gm/day combined
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 21327344

Group type: EXPERIMENTAL
Intervention: Objects with strong perceptual features at decision points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objects with strong perceptual features at non-decision points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separation of perceptual and spatial features
Number of subjects: 0
Study: 19801363

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists (exenatide, liraglutide)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (sitagliptin, alogliptin, saxagliptin)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Monotherapy (diet and exercise)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Combination therapy (oral antihyperglycemic regimens)
Number of subjects: 27
Study: 19281053

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 15780108

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 179

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Calcification score
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Diabetes, C-reactive protein (CRP), diastolic blood pressure, gender, smoking, hypertension
Number of subjects: 179
Study: 12032025

Group type: EXPERIMENTAL
Intervention: Ondansetron continuous infusion (1 mg. mL(‐1). h(‐1))
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline (Control Group T)
Number of subjects: 59
Study: 9442775

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (5 fractions of 200 cGy 6 MV external beam photons)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 91
Study: 7633300

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment at Clinic 2 (long-term maintenance)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Time-limited treatment aimed at abstinence at Clinic 1
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Methadone dose of 80 mg/day
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Average doses prescribed in Clinic 1 (lower doses)
Number of subjects: 202
Study: 2520344

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (approximately 28 mg delivered into the mouth)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (the diluent)
Number of subjects: 16
Study: 238278

Group type: EXPERIMENTAL
Intervention: Trimepranol (15 mg daily for 16 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (during control period)
Number of subjects: 0
Study: 30861617

Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 500
Study: 29681434

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg b.i.d. plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Number of subjects: 76
Study: 28886745

Group type: EXPERIMENTAL
Intervention: Active drug (optimal dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26259064

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) drugs
Number of subjects: 286

Group type: COMPARATOR
Intervention: Non-TCM hospitals
Number of subjects: 286
Study: 23560491

Group type: EXPERIMENTAL
Intervention: Strength exercise (Group 2) - training load of 40% of one repetition maximum (1RM) with anklets, three series of 15 repetitions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Group 3) - pedaled seated in the dialysis seat for 20 min on an ergometric bicycle, intensity regulated by perceived effort scale
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Group 1) - no physical training
Number of subjects: 32